Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Moxifloxacin
Drug ID BADD_D01501
Description Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Indications and Usage For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
Marketing Status Prescription; Discontinued
ATC Code J01MA14; S01AE07
DrugBank ID DB00218
KEGG ID D08237
MeSH ID D000077266
PubChem ID 152946
TTD Drug ID D0ZV0Z
NDC Product Code 50090-3147; 0904-6406; 0378-5430; 65977-0038; 12527-0517; 17478-519; 72189-334; 72789-233; 50090-5279; 60505-0582; 67296-1679; 65862-840; 61919-553; 68180-422; 68180-421; 63629-8357; 72189-321; 72189-076; 55111-112
Synonyms Moxifloxacin | 1-Cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | Octegra | Proflox | Moxifloxacin Hydrochloride | Avelox | Avalox | Izilox | Actira | BAY 12-8039 | BAY 12 8039 | BAY-12-8039 | BAY 128039 | BAY-128039 | BAY128039
Chemical Information
Molecular Formula C21H24FN3O4
CAS Registry Number 151096-09-2
SMILES COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Activated partial thromboplastin time prolonged13.01.02.001--
Agitation19.06.02.001; 17.02.05.012--
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase increased13.03.01.003--
Alveolitis allergic22.01.01.002; 10.01.03.008--Not Available
Amylase decreased13.05.01.001--Not Available
Amylase increased13.05.01.009--
Anaemia01.03.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.0010.002313%
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.0030.000578%Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Angioedema23.04.01.001; 10.01.05.0090.000578%Not Available
Anxiety19.06.02.002--
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.0010.000868%
Aspartate aminotransferase increased13.03.01.006--
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Atrial fibrillation02.03.03.002--
Back pain15.03.04.005--
Basophil count increased13.01.06.002--Not Available
Blepharospasm17.17.02.001; 06.05.01.0010.001157%Not Available
Blindness17.17.01.003; 06.02.02.001--Not Available
Blister23.03.01.001; 12.01.06.0020.000868%Not Available
Blood albumin13.09.01.012--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 8 Pages